The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T- and natural killer-cell lymphomas

Annals of Hematology

Volumn 87, Issue 12, 2008, Pages 985-990

  Chen, Ya Ping ^a   Chang, Kung Chao ^a   Su, Wu Chou ^a   Chen, Tsai Yun ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Mature T and NK cell lymphoma; PDGFRA; Platelet derived growth factor receptor alpha

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RECEPTOR SUBTYPE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NATURAL KILLER CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; T CELL LYMPHOMA; TISSUE SECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; T-LYMPHOCYTES;

EID: 55649091842     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0539-z     Document Type: Article

References (30)

1. Cheng AL, Chen YC, Wang CH, Su IJ, Hsieh HC, Chang JY et al (1989) Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades - should peripheral T-cell lymphoma be considered separately? J Clin Oncol 7:725-731
2. Lymphoma Study Group of Japanese Pathologists (2000) The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities. Pathol Int 50:696-702 doi: 10.1046/ j.1440-1827.2000.01108.x
3. Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Non-Hodgkin's Lymphoma Classification Project et al (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 13:140-149 doi: 10.1093/annonc/mdf033
4. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briàre J, Haioun C et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92:76-82
5. Lopez-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo JM et al (1998) Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 9:849-855 doi: 10.1023/A:1008418727472
6. Alvarez RH, Kantarjian HM, Cortes JE (2006) Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 81:1241-1257
7. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316
8. Heidaran MA, Beeler JF, Yu JC, Ishibashi T, LaRochelle WJ, Pierce JH et al (1993) Differences in substrate specificities of alpha and beta platelet-derived growth factor (PDGF) receptors. Correlation with their ability to mediate PDGF transforming functions. J Biol Chem 268:9287-9295
9. Uren A, Yu JC, Gholami NS, Pierce JH, Heidaran MA (1994) The alpha PDGFR tyrosine kinase mediates locomotion of two different cell types through chemotaxis and chemokinesis. Biochem Biophys Res Commun 204:628-634 doi: 10.1006/bbrc.1994.2505
10. Yu J, Moon A, Kim HR (2001) Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. Biochem Biophys Res Commun 282:697-700 doi: 10.1006/bbrc.2001.4622
11. Yao R, Cooper GM (1995) Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267:2003-2006 doi: 10.1126/science.7701324
12. Raines EW (2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15:237-254 doi: 10.1016/j.cytogfr.2004.03.004
13. Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15:255-273 doi: 10.1016/ j.cytogfr.2004.03.006
14. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A (2003) PDGF receptors as cancer drug targets. Cancer Cell 3:439-443 doi: 10.1016/ S1535-6108(03)00089-8
15. Lewis NL (2007) The platelet-derived growth factor receptor as a therapeutic target. Curr Oncol Rep 9:89-95 doi: 10.1007/s11912-007-0003-6
16. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G et al (2002) Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034-3038
17. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC et al (2003) Imatinib for systemic mast-cell disease. Lancet 362:535-536 doi: 10.1016/S0140-6736(03)14115-3
18. Piccaluga PP, Agostinelli C, Zinzani PL, Baccarani M, Dalla Favera R, Pileri SA (2005) Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. Lancet Oncol 6:440 doi: 10.1016/S1470-2045(05)70213-8
19. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P et al (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357-5364 doi: 10.1200/JCO.2005.14.068
20. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710 doi: 10.1126/science.1079666
21. Brown RE, Nazmi RK (2002) The Reed-Steinberg cell: Molecular characterization by proteomic analysis with therapeutic implications. Ann Clin Lab Sci 32:339-351
22. Renne C, Willenbrock K, Kuppers R, Hansmann ML, Bräuninger A (2005) Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood 105:4051-4059 doi: 10.1182/blood-2004-10-4008
23. Karabatsou K, Pal P, Dodd S, Mat A, Haylock B, Aguirreburualde M et al (2006) Expression of survivin, platelet-derived growth factor A (PDGF-A) and PDGF receptor alpha in primary central nervous system lymphoma. J Neuro-Oncol 79:171-179 doi: 10.1007/s11060-005-9102-0
24. Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S et al (2007) Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117:823-834 doi: 10.1172/JCI26833
25. Jaffe ES (2006) Pathobiology of peripheral T-cell lymphomas. Hematology (Am Soc Hematol Educ Program) 2006:317-322 doi: 10.1182/ asheducation-2006.1.317
26. Gronwald RG, Adler DA, Kelly JD, Disteche CM, Bowen-Pope DF (1990) The human PDGF receptor alpha-subunit gene maps to chromosome 4 in close proximity to c-kit. Hum Genet 85:383-385 doi: 10.1007/BF00206767
27. Kawagishi J, Kumabe T, Yoshimoto T, Yamamoto T (1995) Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. Genomics 30:224-232 doi: 10.1006/geno.1995.9883
28. Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C et al (2006) Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25:2060-2069 doi: 10.1038/sj.onc.1209232
29. Liegl B, Gully C, Reich O, Nogales FF, Beham A, Regauer S (2007) Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations. Histopathology 50:448-452 doi: 10.1111/j.1365-2559.2007.02634.x
30. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502 doi: 10.1038/nrd839